In 2019, the IKWG published updated guidelines regarding the analytical validity and clinical utility of Ki-67 in the clinical care of breast cancer patients, recommending that Ki-67 only be used in a single clinical setting if intra-laboratory analytic validity can be achieved [2]. The gene discussed is MKI67; the disease is breast carcinoma.